Main content

    Amyotrophic and Primary Lateral Sclerosis Clinical Trials

    Sutter Health participates in clinical trials related to Amyotrophic Lateral Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: Multicenter ALS Cohort of Oxidative Stress and Disease Progression
    Description: The purpose of this study is to collect information to try to help find out whether or not there are certain factors that affect the rate the disease gets worse (disease progression).
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 18 months.
    Status: Active and closed to enrollment
    Location: California Pacific Medical Center
    Contact: Dallas Forshew, 415-309-5178, Email: ForsheD@cpmcri.org

    Title: A study to explore the safety and tolerability of Acthar in patients with Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this Phase II study is to evaluate the safety and tolerability of ACTH in patients with ALS.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 3 years.
    Status: Active and closed to enrollment
    Location: California Pacific Medical Center
    Contact: Marguerite Engel, 415-600-3758, Email: EngleM@cpmcri.org


    Title: A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of NCT01709149 In Patients With Amyotrophic Lateral Sclerosis (ALS)Opens in a new window external site
    Description:The purpose of this research study is to evaluate the safety and effectiveness of NCT01709149 in patients with ALS.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease moderate hand grip weakness. .
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Marguerite Engel 415-600-3758, Email: EngleM@cpmcri.org


    Title: Multicenter PLS Cohort Study of Oxidative Stress and Disease Progression Opens in a new window external site
    Description:The first purpose of this observational study is to collect information to help identify if certain factors affect the rate that the disease worsens (disease progression). This information may also give clues to the underlying cause of the disease.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with a diagnosis of clinically definite primary lateral sclerosis (PLS) who have had symptoms for at least 5 years but not greater than 15 years.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Dallas Forshew, 415-309-5178, Email: FrosheD@cpmcri.org


    Title: Average Volume Assured Pressure Support (AVAPS) in ALS Patients with Early Respiratory Insufficiency: A Randomized Crossover Trial.
    Description: The purpose of the study is to test two different types of nighttime assisted breathing with a BiPAP machine. We are trying to find out if it matters how the breath is delivered by the machine (pressure or volume). The questions we are trying to answer is if one method or the other makes the user more comfortable and if one makes you feel better at night and during the day.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have some early breathing changes that qualify them for nighttime use of a BiPAP machine.
    Status: Active and closed to enrollment
    Location: California Pacific Medical Center
    Contact: Giovanna Kushner 415-600-3983, Email: KushnerG@cpmcri.org


    Title: The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this study is to find out if Nuedexta® will improve the bulbar functions in people with ALS. Bulbar functions include speech, swallowing, and the production of saliva (salivation).
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease and who have difficulty speaking and/or swallowing.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Marguerite Engle 415-600-3758, Email: EngleM@cpmcri.org


    Title: HDE Post-Approval Study (PAS) of NeuRx DPS TM (Diaphragm Pacing System) for ALS. C_FN_Diaphragm Pacing Post Approval Study Opens in a new window external site
    Description: The purpose of this research study is to collect more information about the possible risks and benefits of the NeuRx DPS TM device (Diaphragm Pacing System).
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Dallas Forshew, 415-309-5178, Email: ForsheD@cpmcri.org


    > See All Neurology Clinical Trials by Condition